The phase II DESTINY-CRC02 trial has identified the preferred dosage of single-agent fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive advanced colorectal cancer.
The AMADEUS clinical trial sheds light on how biomarkers can predict how patients respond to immune checkpoint inhibitor treatments like nivolumab and ipilimumab.
Incyte announced positive topline results from the phase III inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide (Revlimid) and rituximab (Rituxan) compared to lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma.
The Multiple Myeloma Research Foundation’s CoMMpass study, a prospective, longitudinal observational study of 1,143 newly diagnosed, previously untreated multiple myeloma patients, revealed critical genetic markers that can better predict disease progression and identify patients at risk of transitioning to more aggressive forms of the disease.
A 12-year observational study which aimed to sequence the genome, exome, and RNA in tumors from patients with multiple myeloma was able to define distinct subtypes of the disease, according to an international team of scientists led by researchers from the Translational Genomics Research Institute, part of City of Hope.
Research from Children’s Medical Center Research Institute at UT Southwestern shows that metastatic kidney cancers rely heavily on mitochondrial metabolism. These findings are contrary to how tumors operate while still in the kidney.Â
A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.Â
Misetionamide, a tumor cell-selective small molecule drug that is broadly active in multiple cancer models, demonstrated excellent monotherapy results as well as synergistic activity with PARP inhibitors and bevacizumab antineoplastic in ovarian cancer in a recent preclinical study.
Esopredict, a test developed by Johns Hopkins Kimmel Cancer Center investigators, could give gastroenterologists insight into which patients with Barrett’s esophagus are likely to progress to esophageal cancer or an abnormal collection of cells called high-grade dysplasia, according to a recent study. This information could help physicians determine how to monitor or manage patients during clinical care.
A study recently published in BJUI Compass found that Unfold AI, an FDA-cleared artificial intelligence algorithm developed by Avenda Health, accurately predicted extracapsular extension risk (ECE) and outperformed conventional methodologies.
